No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 657.7x · 10Y median 402.8x · 81st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:28:40.203Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ProKidney Corp. (PROK) stock was $1.60 as of Oct 6, 2026, 4:00 PM EDT, up 1.27% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -42.2% · 3-year avg -30.7%/yr · 5-year avg -30.6%/yr
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments.
Biotechnology · Winston-Salem, NC
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.12
Revenue Est.
$124600.00
Last Quarter Results
EPS
$-0.15
vs Estimate
$-0.14
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PROK | $538.01M | $1.60 | +1.27% | -42.18% | -30.65% | N/A | N/A |
| 2MNPR | $533.04M | $79.57 | +1.63% | -21.14% | +27.38% | N/A | vs PROK |
| 3DCTH | $531.98M | $15.41 | -2.90% | +42.73% | +10.90% | N/A | vs PROK |
| 4NVCT | $531.52M | $20.03 | -6.36% | +253.76% | N/A | N/A | vs PROK |
| 5STTK | $529.58M | $5.86 | -9.85% | +175.26% | -20.11% | N/A | vs PROK |
| 6PHAT | $548.51M | $6.78 | +1.19% | -44.97% | -26.93% | N/A | vs PROK |
forward FY estimate
N/A
$150000.00
vs Estimate
$186250.00
Consensus Rating
Based on 6 analysts
Average Price Target
$6.25
+290.6% upside
Low
$1.00
Current
$1.60
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.50 | $-0.33 | $-0.17 | 4 |
| Quarter ending Dec 2026 | $-0.49 | $-0.33 | $-0.17 | 4 |
| Quarter ending Mar 2027 | $-0.46 | $-0.14 | $-0.04 | 1 |
| Quarter ending Jun 2027 | $-0.36 | $-0.11 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.67 | $-0.66 | $-0.65 | 3 |
| FY 2027 | $-1.22 | $-0.66 | $-0.40 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $54214.00 | $124600.00 | $341197.00 | 3 |
| Quarter ending Dec 2026 | $197276.00 | $453400.00 | $1.24M | 3 |
| Quarter ending Mar 2027 | $87021.00 | $200000.00 | $547668.00 | 1 |
| Quarter ending Jun 2027 | $87021.00 | $200000.00 | $547668.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $370604.00 | $507143.00 | $780219.00 | 5 |
| FY 2027 | $6805.00 | $411833.00 | $1.22M | 3 |
